Advanstar
, the pre-eminent publisher of pharmaceutical life science publications for over 50 years, will become the first B2B publisher to embrace the innovative new online Credibility Review Business Marketplace platform developed by Dun & Bradstreet Credibility Corp., the leading provider of credit building and credibility solutions for businesses.
The new Pharmaceutical Technology and BioPharm International
Marketplace
will be vastly different from traditional online B2B directories. It is a vibrant online community that brings pharmaceutical buyers and suppliers together with Industry-leading thought leadership content from the publications, in-depth product information from suppliers and real time social media features that allow members to integrate their company social media feeds into their profiles. Buyers will have the ability to rate and comment on products and services from suppliers.
"We are very excited about this opportunity. Given the high costs of developing eDirectories and continually upgrading and supporting these platforms across a wide array of publications, an alternative that leveraged lower upfront costs and scalability with speed to market was very attractive," said Advanstar Executive Vice-President, Ron Wall.
According to eMarketer's latest report, digital spending in pharmaceutical and healthcare marketing is forecasted to grow 57% to $2.48 billion by 2016. "Our vision is to create the largest and most dynamic communities of buyers and suppliers with Dun & Bradstreet Credibility Corp., so we can take full advantage of this spending growth," said Wall.
According to Jeff Stibel, Chairman and CEO, Dun & Bradstreet Credibility Corp., "What we offer is a highly respected and branded platform with enhanced credibility data and information from our database, world class development expertise that will allow all of the Marketplace sites to benefit from ongoing upgrades and enhancements and a seamless integration of social media."
The new Pharmaceutical Technology / BioPharm International Marketplace will concentrate on business information and news on companies in the following key categories:
Advanstar Life Sciences group will launch additional eDirectories supported by their other publications on the Dun & Bradstreet Credibility Review Marketplace in the coming months.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.